You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 119 No. 2, February 1993 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Orbital Decompression for Preservation of Vision in Graves' Ophthalmopathy

Douglas A. Girod, MD; James C. Orcutt, MD, PhD; Charles W. Cummings, MD

Arch Otolaryngol Head Neck Surg. 1993;119(2):229-233.


Abstract

• Graves' ophthalmopathy (thyroid eye disease) can result in progressive visual loss. The University of Washington (Seattle) experience in orbital decompression was reviewed for the years 1983 through 1990 to determine overall safety and outcome. Twenty patients underwent transantral decompression of 36 orbits for either steroid therapy failure, steroid therapy intolerance, or recurrence of optic neuropathy with tapering of the steroid therapy. Decompression successfully improved visual function in 33 of the orbits (92%) and a second decompression procedure was successful in another two (5%) of the orbits (6%). There were no major complications or cases of decreased visual function. Diplopia, present preoperatively in 17 patients (85%), was improved in eight patients (47%) and unchanged in nine patients (53%). However, of the three patients without preoperative diplopia (15%), one had development of new-onset diplopia postoperatively. Transantral decompression of the orbit offers a safe and effective therapeutic modality for vision-threatening Graves' ophthalmopathy.

(Arch Otolaryngol Head Neck Surg. 1993;119:229-233)



Author Affiliations

From the Departments of Otolaryngology–Head and Neck Surgery (Drs Girod and Cummings) and Ophthalmology (Dr Orcutt), University of Washington, Seattle. Dr Girod is now with the Department of Otolaryngology–Head and Neck Surgery, Naval Hospital Oakland, Calif. Dr Cummings is now with the Department of Otolaryngology–Head and Neck Surgery, The Johns Hopkins University, Baltimore, Md.


Footnotes

Accepted for publication August 20, 1992.

Read before the American Society for Head and Neck Surgery at the Combined Otolaryngological Spring Meetings, Waikoloa, Hawaii, May 8, 1991.

Reprint requests to Department of Ophthalmology, RJ-10, University of Washington, Seattle, WA 98195 (Dr Orcutt).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.